Summer Sale
50% off Premium Yearly
NYSE:DOCS
Doximity (DOCS)
Financials 
Technical Analysis 
Jun 16, 2026, 12:00 amThis summary was created by AI, based on 1 opinions in the last 12 months.
The financial outlook for Doximity (DOCS-N) appears to be cautionary as recent expert reviews indicate significant concerns regarding its valuation. One expert noted that the stock is still deemed too expensive despite the company's potential, particularly in light of a disappointing performance in its last quarter. This has led to skepticism about its future growth prospects, as investors are advised to weigh these financial results heavily when considering their investment decisions. Overall, there seems to be a consensus that the current price does not adequately reflect the company's value based on its recent performance, pointing towards a need for strategic re-evaluation. Investors may want to proceed with caution as they assess the risk-reward ratio of holding this stock amidst shaky financial indicators.
DOCS has erased earlier gains from its last earnings report, amid the market drawdown, but it continues to be on a long-term uptrend, and forward sales and earnings estimates are strong. Analyst estimates have been trending higher in the past year, margins have been expanding, and it generates decent cash flows. It has a good balance sheet, but it is not cheap at 38X forward earnings. For a long-term investor, we would be comfortable holding here given its fundamental strength.
Unlock Premium - Try 5i Free
Up 38% since IPO in fall 2021. Shares got killed last year during inflation and rate hikes. Has since rebounded. It's been a round trip. Their last report was solid, but guidance was ugly, given a delay in their new telemedicine product given regulatory interference. But they've beaten every quarter. Pricey at 47x PE 2023 but are profitable.
- «
- ‹
- 1
- ›
- »
Doximity (DOCS) Frequently Asked Questions
What is Doximity stock symbol?
Doximity is a American stock, trading under the symbol DOCS (previously DOCS-N on Stockchase) on the New York Stock Exchange (DOCS). It is usually referred to as NYSE:DOCS or DOCS
Is Doximity a buy or a sell?
In the last year, 1 stock analyst issued a Buy, Sell, or Hold rating on DOCS (previously DOCS-N on Stockchase). 0 analysts recommended to BUY and 1 analyst recommended to SELL the stock. The latest stock analyst rating is . Read the latest stock experts' ratings for Doximity.
Is Doximity a good investment or a top pick?
Doximity was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Doximity.
Why is Doximity stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Doximity.
Is Doximity worth watching?
Doximity is covered by Stockchase experts and is worth watching.
What is Doximity stock price?
On 2026-06-16, Doximity (DOCS) stock closed at a price of $20.89.
Is still too expensive. Their last quarter wasn't that good.